Literature DB >> 20154484

[Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents].

Kenji Ikeda1, Takuji Okusaka, Masafumi Ikeda, Manabu Morimoto.   

Abstract

SM-11355 is a cisplatin derivative with high affinity for iodized ethyl esters of fatty acids of poppyseed oil. Clinical trials have shown that SM-11355 is effective for treatment of hepatocellular carcinoma. Transcatheter arterial chemoembolization is commonly used in combination with embolizing agents, but concomitant use of SM-11355 and embolizing agents has not been evaluated in previous trials. In this study, the safety and efficacy of SM-11355 in combination with embolizing agents were investigated in 10 patients with hepatocellular carcinoma. An anti-tumor effect of TE4 was achieved in 4 of 9 patients and no serious adverse events were observed, indicating that this therapy can be used safely for hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154484

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.

Authors:  Shiro Miyayama; Masashi Yamashiro; Yoshihiro Shibata; Masahiro Hashimoto; Miki Yoshida; Kazunobu Tsuji; Fumihito Toshima; Osamu Matsui
Journal:  Jpn J Radiol       Date:  2012-01-07       Impact factor: 2.374

2.  Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model.

Authors:  Yuki Tomozawa; Norihisa Nitta; Shinji Ohta; Hideji Otani; Shobu Watanabe; Akinaga Sonoda; Keiko Tsuchiya; Ayumi Nitta-Seko; Masashi Takahashi; Kiyoshi Murata
Journal:  Jpn J Radiol       Date:  2013-07-05       Impact factor: 2.374

3.  Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.

Authors:  Masafumi Ikeda; Masatoshi Kudo; Hiroshi Aikata; Hiroaki Nagamatsu; Hiroshi Ishii; Osamu Yokosuka; Takuji Torimura; Manabu Morimoto; Kenji Ikeda; Hiromitsu Kumada; Tosiya Sato; Ikuko Kawai; Toru Yamashita; Hiroshi Horio; Takuji Okusaka
Journal:  J Gastroenterol       Date:  2017-08-01       Impact factor: 7.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.